ESA ineligible
Showing 1 - 25 of 453
MDS, MDS Trial in France (Luspatercept Injection [Reblozyl], Eprex)
Recruiting
- MDS
- Myelodysplastic Syndromes
- Luspatercept Injection [Reblozyl]
- Eprex
-
Amiens, France
- +30 more
May 19, 2022
Anemia Trial in Anyang-si (Ferric Derisomaltose Injection, Darbepoetin Alfa Injection)
Recruiting
- Anemia
- Ferric Derisomaltose Injection
- Darbepoetin Alfa Injection
-
Anyang-si, Korea, Republic ofHallym University Medical Center
Mar 13, 2023
Erythropoiesis Stimulating Agents for Anemia Management in
Completed
- Anemia of Chronic Kidney Disease
- +2 more
-
Giza, Egyptthe Memorial Souad Kafafi University Hospital
Jan 24, 2023
MDS Trial in Worldwide (Luspatercept, Epoetin Alfa)
Not yet recruiting
- Myelodysplastic Syndromes
- Luspatercept
- Epoetin Alfa
-
Concord, California
- +100 more
Jul 20, 2023
Plasma Cell Leukemia Trial in Tianjin (anti-BCMA CAR-T, VRD-based regimen)
Recruiting
- Plasma Cell Leukemia
- anti-BCMA CAR-T
- VRD-based regimen
-
Tianjin, ChinaInstitute of Hematology and Blood Diseases Hospital Chinese Acad
Aug 4, 2023
Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma Trial in China (Relmacabtagene
Not yet recruiting
- Lymphoma, Large B-Cell, Diffuse
- +3 more
- Relmacabtagene Autoleucel
- +2 more
-
Guangzhou, Guangdong, China
- +12 more
Oct 24, 2023
Medium Cut-off Dialyzers Versus High-Flux Dialyzers on Clinical
Completed
- Hemodialysis-Associated Pruritus
- +4 more
- Dialysis using the Theranova-400 device.
- Dialysis using the FX80 device.
-
Şanlıurfa, Karaköprü, TurkeyMehmet Akif Inan Training and Research Hospital
Jan 13, 2023
MDS Trial in Tampa (Canakinumab Injection, Darbepoetin Alfa)
Recruiting
- Myelodysplastic Syndromes
- Canakinumab Injection
- Darbepoetin Alfa
-
Tampa, FloridaMoffitt Cancer Center
Nov 21, 2022
Multiple Myeloma Trial in Tianjin (anti-BCMA CAR-T, VRD)
Recruiting
- Multiple Myeloma
- anti-BCMA CAR-T
- VRD
-
Tianjin, ChinaInstitute of Hematology and Blood Diseases Hospital Chinese Acad
May 5, 2023
Anemia of Chronic Kidney Disease Trial in Hackensack (Vadadustat)
Suspended
- Anemia of Chronic Kidney Disease
-
Hackensack, New JerseyResearch Site
Aug 23, 2022
NMIBC Trial in Beijing (RC48-ADC in Combination with gemcitabine)
Recruiting
- NMIBC
- RC48-ADC in Combination with gemcitabine
-
Beijing, Beijing, ChinaPeking University First Hosptital
Jul 10, 2023
Anemia Associated With Chronic Kidney Disease Trial in United States (Roxadustat)
Withdrawn
- Anemia Associated With Chronic Kidney Disease
-
Chicago, Illinois
- +3 more
Jun 29, 2022
Anemia of Chronic Kidney Disease Trial in Hackensack (vadadustat)
Suspended
- Anemia of Chronic Kidney Disease
-
Hackensack, New JerseyResearch Site
Aug 23, 2022
Acute Myeloid Leukemia Trial in Worldwide (Magrolimab, Venetoclax, Azacitidine)
Recruiting
- Acute Myeloid Leukemia
- Magrolimab
- +3 more
-
Little Rock, Arkansas
- +82 more
Jan 17, 2023
Non-Hodgkin Lymphoma Trial in Cologne (Tafasitamab, Lenalidomide, Rituximab)
Not yet recruiting
- Non-Hodgkin Lymphoma
- Tafasitamab
- +3 more
-
Cologne, GermanyUniversity of Cologne
Oct 14, 2022
Anemia in Dialysis-dependent CKD Patients Trial in Alexandria (Roxadustat)
Recruiting
- Anemia in Dialysis-dependent CKD Patients
-
Alexandria, EgyptAlexandria University
Oct 29, 2023
Urinary Bladder Tumors Trial in Worldwide (Durvalumab, Olaparib, Placebo)
Active, not recruiting
- Urinary Bladder Neoplasms
- Durvalumab
- +2 more
-
Birmingham, Alabama
- +44 more
Dec 21, 2022
SCCHN, Squamous Cell Carcinoma Trial in Birmingham (Cisplatin)
Recruiting
- SCCHN
- Squamous Cell Carcinoma
-
Birmingham, AlabamaUniversity of Alabama at Birmingham
Jan 5, 2023
Urothelial Cancer Trial in Beijing (Atezolizumab, RO7247669, Tiragolumab)
Recruiting
- Urothelial Cancer
- Atezolizumab
- +2 more
-
Beijing, ChinaBeijing Cancer Hospital
Jan 18, 2023